The February top 10 features news of the recent Japanese randomised control trial results, which support the use of mechanical thrombectomy in ischaemic stroke patients. Other highlights include an exploration of innovations in treating and diagnosing small renal masses by Vinson Wai-Shun Chan and Tze Min Wah, as well as Fluidx Medical’s announcement of “very promising” results from the company’s GPX-Clear embolic device in-vivo research.
A new study from Japan has become the first randomised controlled trial to demonstrate the effectiveness of endovascular mechanical thrombectomy procedures in patients who have severe strokes involving clots in one or more large brain arteries.
A recent retrospective analysis published in Melanoma Research has found that percutaneous hepatic perfusion with melphalan for the treatment of metastatic uveal melanoma offers a hepatic response rate of 66.7% and good progression-free survival.
Fluidx Medical Technology has announced the results of the GPX-Clear embolic device in-vivo research which uses the base GPX technology and incorporates an intermediate-term radiopacity agent, as described by the company.
Concept Medical has announced that the SIRONA randomised controlled trial (head-to-head comparison of sirolimus versus paclitaxel drug-eluting balloon angioplasty in the femoropopliteal artery) has completed half the targeted enrolment.
In light of recent and upcoming developments, Vinson Wai-Shun Chan and Tze Min Wah (Leeds, UK) explore the evidence and latest progress in renal tumour biopsy and discuss the treatment of small renal masses more broadly.
An associate professor of Radiology at the Division of Interventional Radiology, Nuovo Santa Chiara University Hospital, Pisa, Italy, Laura Crocetti is also an internationally recognised ablation expert. Here she answers questions posed by Interventional News.
Cerenovus—a neurovascular firm that forms part of Johnson & Johnson Medical Devices Companies—has announced the launch of Emboguard, the next-generation balloon guide catheter to be used in endovascular procedures, including those for patients with acute ischaemic stroke.
Preliminary late-breaking research presented at this year’s International Stroke Conference (9–11 February, New Orleans, USA) shows that mechanical removal of blood clots reduced post-stroke disability in nearly half of “all-comer” real-world stroke patients.
MedAlliance has acquired its partner MDK Medical, a Japanese vascular specialist company. MDK Medical has previously worked closely with MedAlliance in developing Japanese clinical studies for the novel sirolimus drug-eluting balloon—the Selution SLR— for the treatment of peripheral arterial disease.
Inari Medical has announced that the first patient has been enrolled in PEERLESS prospective, randomised controlled trial comparing the outcomes of patients with intermediate-high risk pulmonary embolism treated with the FlowTriever system versus catheter-directed thrombolysis.